QIAGEN N.V. (QGEN)
Qiagen N.V. (QGEN) Presents at Evercore 8th Annual Healthcare Conference Transcript
Qiagen N.V. (QGEN) Presents at Evercore 8th Annual Healthcare Conference Transcript
Qiagen N.V. (QGEN) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Qiagen N.V. (QGEN) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Qiagen N.V. (QGEN) Deep Dive Into Sample Technologies: Leadership, Innovation and Future Expansion Transcript
Qiagen N.V. ( QGEN ) Deep Dive Into Sample Technologies: Leadership, Innovation and Future Expansion November 21, 2025 9:00 AM EST Company Participants Domenica Martorana - Associate Director of Global Investor Relations Thierry Bernard - CEO, MD & Member of Management Board Daniel Wendorff John Gilardi - VP & Head of Corporate Communications Michael Scheffler Nitin Sood - Senior VP & Head of Product Portfolio & Innovation Fernando Beils Justus Krause-Harder Presentation Domenica Martorana Associate Director of Global Investor Relations Welcome to our next QIAGEN Deep Dive.
Qiagen N.V. (QGEN) Presents at Jefferies London Healthcare Conference 2025 Transcript
Qiagen N.V. ( QGEN ) Jefferies London Healthcare Conference 2025 November 19, 2025 5:30 AM EST Company Participants Roland Sackers - CFO, MD & Member of Management Board Daniel Wendorff John Gilardi - VP & Head of Corporate Communications Conference Call Participants Tycho Peterson - Jefferies LLC, Research Division Presentation Tycho Peterson Jefferies LLC, Research Division Welcome, everybody.
CellBxHealth rises on Qiagen tie-up to push Parsortix into more drug-development projects
Shares in CelLBxHealth PLC (AIM:CLBX, NSX:ANPCY, OTCQB:ANPCF) climbed 7% to 1.93p after the company unveiled a collaboration with Qiagen designed to bring its Parsortix circulating tumour cell platform to a wider range of pharmaceutical partners. The agreement gives Qiagen the ability to bundle Parsortix into projects alongside its own molecular technologies, including polymerase chain reaction, digital polymerase chain reaction and next-generation sequencing.
CellBxHealth strikes co-marketing deal with Qiagen to widen use of Parsortix cancer platform
CelLBxHealth PLC (AIM:CLBX, NSX:ANPCY, OTCQB:ANPCF) has agreed a collaboration and co-marketing deal with Qiagen that will allow the diagnostics group to promote the UK company's Parsortix system to drugmakers, opening the door to new projects in circulating tumour cell research and early diagnostic development. The non-exclusive agreement enables Qiagen to offer the Parsortix platform to its pharmaceutical partners as part of projects that combine circulating tumour cell enrichment with Qiagen's polymerase chain reaction, digital polymerase chain reaction and next-generation sequencing technologies.
Qiagen N.V. (QGEN) Presents at 7th Annual Wolfe Research Healthcare Conference Transcript
Qiagen N.V. ( QGEN ) 7th Annual Wolfe Research Healthcare Conference November 17, 2025 12:40 PM EST Company Participants Thierry Bernard - CEO, MD & Member of Management Board Conference Call Participants Douglas Schenkel - Wolfe Research, LLC Presentation Douglas Schenkel Wolfe Research, LLC All right.
Qiagen (QGEN) International Revenue in Focus: Trends and Expectations
Evaluate Qiagen's (QGEN) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.
Why Qiagen (QGEN) is a Top Value Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Here's What Key Metrics Tell Us About Qiagen (QGEN) Q3 Earnings
Although the revenue and EPS for Qiagen (QGEN) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Analysts Estimate Qiagen (QGEN) to Report a Decline in Earnings: What to Look Out for
Qiagen (QGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
QGEN vs. ACAD: Which Stock Is the Better Value Option?
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Qiagen (QGEN) and Acadia Pharmaceuticals (ACAD). But which of these two stocks is more attractive to value investors?
